Illumina, Inc.: Mixed — EPS $1.62, Revenue $1.13B
Mixed ResultQ3 2026 · After-market
Did Illumina, Inc. (ILMN) beat earnings today?
It was a mixed report for Q3 2026 — Illumina, Inc. (ILMN) beat on EPS but missed on revenue.
Earnings Per Share+19.12% surprise
$1.62Actual
Expected: $1.36
vs. year ago +20.9%
Total Revenue-1.83% surprise
$1.13BActual
Expected: $1.15B
vs. year ago +4.2%
Released Oct 29 · 4:05 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $1.13B | $1.08B | +4.2% |
| Revenue detail — reported lines | |||
| └─Product revenue | $946.00M | $927.00M | +2.0% |
| └─Service and other revenue | $183.00M | $157.00M | +16.6% |
| Net income | $220.00M | $150.00M | +46.7% |
| GAAP Basic EPS | $1.46 | $0.98 | +49.0% |
| GAAP Diluted EPS | $1.43 | $0.98 | +45.9% |
| Non-GAAP Diluted EPS | $1.62 | $1.34 | +20.9% |
| Non-GAAP Diluted EPS excluding tariff refunds | $1.44 | $1.34 | +7.5% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2026 Guidance |
|---|---|---|
| Total revenue | — | $4.64B-$4.66B (prev. $4.60B-$4.64B) |
| Organic revenue growth | — | greater than 4% (prev. greater than 4%) |
| ROW organic revenue growth | — | greater than 5% (prev. greater than 5%) |
| Non-GAAP operating margin | — | 23.6% (prev. 23.4%-23.6%) |
| Non-GAAP diluted EPS | — | $5.40-$5.45 (prev. $5.30-$5.40) |
Business Highlights
- ➤Robust NovaSeq X placements supported quarterly execution.
- ➤Healthy clinical demand continued during the quarter.
- ➤Innovation is broadening the value of the Illumina ecosystem.
- ➤Illumina is working with customers to advance AI in human biology.
- ➤Products serve research, clinical, applied, oncology, reproductive health, and agriculture markets.
Management Commentary
Jacob Thaysen, Chief Executive Officer
“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance,”
Jacob Thaysen, Chief Executive Officer
“As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.”